Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Kinase drug discovery approaches in chronic myeloproliferative disorders

Oncogene volume 28, pages 2305–2313 (2009)Cite this article

Abstract

Myeloproliferative disorders (MPDs) are clonal malignancies that arise from hematopoietic progenitors and characterized by overproduction of mature, functional blood cells. These disorders can be broadly characterized into Philadelphia chromosome-positive (Ph(+)) or negative (Ph(−)) genetic groupings. Chronic myeloid leukemia (CML) is a Ph(+) MPD that is defined on the basis of its molecular lesion, the BCR-ABL fusion gene. Inhibitors directed at the constitutive kinase activity of BCR-ABL have been shown to be disease modifying in CML and have dramatically altered the standard of care for this leukemia. The three main Ph(−) MPDs are polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). The key features of these Ph(−) MPDs are an increased red blood cell mass in PV, a high platelet count in ET and bone marrow fibrosis in PMF, respectively. These disorders also share many clinical features such as long clinical course, increased risk for thrombosis, hemorrhage and elevated risk of leukemic transformation. Interest in these disorders has been ignited by the recent discovery of activating mutations in the tyrosine kinase gene, JAK2, in the predominance of Ph(−) MPD patients and has highlighted JAK2 as a therapeutic intervention point for drug discovery efforts with selective kinase inhibitors. This review will focus on the comparison of Ph(+) and Ph(−) MPDs, drug discovery and development efforts targeting these disorders, and will assess the new opportunities for targeted therapies for these diseases.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Abdel-Wahab OI, Levine RL . (2009). Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med 60: 233–245.

    Article  CAS  Google Scholar 

  • Baccarani M, Pane F, Saglio G . (2008). Monitoring treatment of chronic myeloid leukemia. Haematologica 93: 161–169.

    Article  CAS  Google Scholar 

  • Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D et al (1983). Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukemia. Nature 306: 277–280.

    Article  CAS  Google Scholar 

  • Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. (2005). Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054–1061.

    Article  CAS  Google Scholar 

  • Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L et al. (2006). Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 66: 11156–11165.

    Article  CAS  Google Scholar 

  • Campbell PJ, Green AR . (2005). The myeloproliferative disorders. N Engl J Med 355: 2452–2466.

    Article  Google Scholar 

  • Carroll M, Tomasson MH, Barker GF, Golub TR, Gilliland DG . (1996). The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci USA 93: 14845–14850.

    Article  CAS  Google Scholar 

  • Cervantes F, Mesa R, Barosi G . (2007). New old treatment modalities in primary myelofibrosis. Cancer J 13: 377–383.

    Article  CAS  Google Scholar 

  • Cervantes F, Passamonti F, Barosi G . (2008). Life expectancy prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia 22: 905–914.

    Article  CAS  Google Scholar 

  • Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C . (1991). Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability main characteristics in a series of 218 patients. Acta Haematol 85: 124–127.

    Article  CAS  Google Scholar 

  • Chen J, Deangelo DJ, Kutok JL, Williams IR, Lee BH, Wadleigh M et al. (2004). PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA 101: 14479–14484.

    Article  CAS  Google Scholar 

  • Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. (2003). A tyrosine kinase created by fusion of the PDGFRA FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201–1214.

    Article  CAS  Google Scholar 

  • Doesch C, Krämer B, Geisler T, May AE, Kroeber SM, Kandolf R et al. (2008). Challenges in the treatment of patients with essential thrombocythemia acute coronary syndrome. J Thromb Thrombolysis 25: 193–197.

    Article  Google Scholar 

  • Damshek W . (1951). Some speculations on the myeloproliferative syndromes. Blood 6: 372–375.

    Google Scholar 

  • Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. (2001). Efficacy safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031–1037.

    Article  CAS  Google Scholar 

  • Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM . (1999). The biology of chronic myeloid leukemia. N Engl J Med 341: 164–172.

    Article  CAS  Google Scholar 

  • Finazzi G . (2008). Essential thrombocythemia. Cancer Treat Res 142: 51–68.

    PubMed  Google Scholar 

  • Finazzi G, Barbui T . (2007). How I treat patients with polycythemia vera. Blood 109: 5104–5111.

    Article  CAS  Google Scholar 

  • Geron I, Abrahamsson AE, Barroga CF, Kavalerchik E, Gotlib J, Hood JD et al. (2008). Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell 13: 321–330.

    Article  CAS  Google Scholar 

  • Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ . (2007). MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109: 500–502.

    Article  CAS  Google Scholar 

  • Goerttler PS, Kreutz C, Donauer J, Faller D, Maiwald T, März E et al. (2005). Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF-E2. Br J Haematol 129: 138–150.

    Article  CAS  Google Scholar 

  • Golub TR, Barker GF, Lovett M, Gilliland DG . (1994). Fusion of PDGF receptor B to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5 ;12) chromosomal translocation. Cell 77: 307–316.

    Article  CAS  Google Scholar 

  • Guilhot F . (2004). Indications for imatinib mesylate therapy and clinical management. Oncologist 9: 271–281.

    Article  CAS  Google Scholar 

  • Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D et al. (2005). United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353: 33–45.

    Article  CAS  Google Scholar 

  • James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C et al. (2005). A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144–1148.

    Article  CAS  Google Scholar 

  • Johansson P, Kutti J, Andre Asson B, Safai-KutttI S, Vile L, Wedel NH et al. (2004). Trends in the incidence of chronic Philadelphia chromosome negative (Ph-)myeloproliferative disorders in the city of Goteborg, Sweden, during 1983–99. J Int Med 256: 161–165.

    Article  CAS  Google Scholar 

  • Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F et al. (2007). Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110: 3540–3546.

    Article  CAS  Google Scholar 

  • Kantarjian H, Schiffer C, Jones D, Cortes J . (2008). Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 111: 1774–1780.

    Article  CAS  Google Scholar 

  • Knapper S, Burnett AK, Littlewood T, Kell WJ, Agrawal S, Chopra R et al. (2006). A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 108: 3262–3270.

    Article  CAS  Google Scholar 

  • Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. (2005). A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779–1790.

    Article  CAS  Google Scholar 

  • Kutti J, Ridell B . (2001). Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis. Pathol Biol 49: 164–166.

    Article  CAS  Google Scholar 

  • Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL . (2006). JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108: 1652–1660.

    Article  CAS  Google Scholar 

  • Lee FY, Wen ML, Bhide R, Camuso A, Castenada S, Fager K et al. (2005). (BMS-354825) overcomes multiple mechanisms of imatinib resistance in chronic myeloid leukemia (CML). Blood 106: 1994.

    Google Scholar 

  • Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P et al. (2006). -inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 107: 4139–4141.

    Article  CAS  Google Scholar 

  • Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. (2005). Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387–397.

    Article  CAS  Google Scholar 

  • Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K et al. (2004). Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-54825), a dual Src/Abl kinase inhibitor with potent anti-tumor activity in preclinical assays. J Med Chem 47: 6658–6661.

    Article  CAS  Google Scholar 

  • Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S et al. (2005). Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA 102: 18962–18967.

    Article  CAS  Google Scholar 

  • Mesa RA, Barosi G, Cervantes F, Reilly JT, Tefferi A . (2006). Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options. Best Pract Res Clin Haematol 19: 495–517.

    Article  Google Scholar 

  • Mesa RA . (2008). New insights into the pathogenesis and treatment of chronic myeloproliferative disorders. Curr Opin Hematol 15: 121–126.

    Article  CAS  Google Scholar 

  • Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S et al. (2006). The burden of fatigue and quality of life in myeloproliferative disorders. Cancer 109: 68–76.

    Article  Google Scholar 

  • Morinaga K, Yamauchi T, Kimura S, Maekawa T, Ueda T . (2008). Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification. Int J Cancer 122: 2621–2627.

    Article  CAS  Google Scholar 

  • Murray PJ . (2007). The JAK–STAT signaling pathway: input and output integration. J Immunol 178: 2623–2629.

    Article  CAS  Google Scholar 

  • Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y et al. (1995). Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 92: 10560–10564.

    Article  CAS  Google Scholar 

  • Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R et al. (2005). Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 65: 9185–9189.

    Article  CAS  Google Scholar 

  • O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994–1004.

    Article  Google Scholar 

  • O’Hare T, Eide CA, Tyner JW, Corbin AS, Wong MJ, Buchanan S et al. (2008). SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Natl Acad Sci USA 105: 5507–5512.

    Article  Google Scholar 

  • O’Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J et al. (2005). in vitro activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65: 4500–4505.

    Article  Google Scholar 

  • O’Shea JJ, Pesu M, Borie DC, Changelian PS. (2004). A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov 3: 555–564.

    Article  Google Scholar 

  • Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A . (2007). Prevalence and clinicopathologic correlates of JAK 2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 21: 1960–1963.

    Article  CAS  Google Scholar 

  • Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. (2006). MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3: e270.

    Article  Google Scholar 

  • Quintás-Cardama A, Cortes J . (2008). Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones. Leuk Res (in press).

  • Quintas-Cardama A, Kantarjian H, Cortes J . (2006). Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib. Future Oncol 2: 655–665.

    Article  CAS  Google Scholar 

  • Saijo K, Park SY, Ishida Y, Arase H, Saito T . (1997). Crucial role of Jak3 in negative selection of self-reactive T cells. J Exp Med 185: 351–356.

    Article  CAS  Google Scholar 

  • Sawyers CL . (1999). Chronic myeloid leukemia. N Engl J Med 340: 1330–1340.

    Article  CAS  Google Scholar 

  • Sawyers CL . (2005). Making progress through molecular attacks on cancer. Cold Spring Harb Symp Quant Biol 70: 479–482.

    Article  CAS  Google Scholar 

  • Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY et al. (2006). Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66: 473–481.

    Article  CAS  Google Scholar 

  • Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. (2007). JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356: 459–468.

    Article  CAS  Google Scholar 

  • Shah NP, Kim DW, Kantarjian HM, Rousselot P, Dorlhiac-Llacer PE, Milone JH et al. (2007). Dasatinib 50 mg or 70 mg BID compared to 100 mg or 140 mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: one-year results of CA180034. J Clin Oncol 25: 7004.

    Article  Google Scholar 

  • Shah NP . (2007). Medical management of CML. Hematology Am Soc Hematol Educ Program 2007: 371–375.

    Article  Google Scholar 

  • Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. (2002). Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117–1125.

    Article  CAS  Google Scholar 

  • Sherbenou DW, Druker BJ . (2007). Applying the discovery of the Philadelphia chromosome. J Clin Invest 117: 2067–2074.

    Article  CAS  Google Scholar 

  • Siendones E, Barbarroja N, Torres LA, Buendía P, Velasco F, Dorado G et al. (2007). Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors. Hematol Oncol 25: 30–37.

    Article  CAS  Google Scholar 

  • Soverini S, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C et al. (2007). Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 92: 401–404.

    Article  CAS  Google Scholar 

  • Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al. (2006). Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354: 2531–2541.

    Article  CAS  Google Scholar 

  • Tefferi A . (2000). Myelofibrosis with myeloid metaplasia. N Engl J Med 342: 1255–1265.

    Article  CAS  Google Scholar 

  • Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY et al. (2005). The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol 131: 320–328.

    Article  CAS  Google Scholar 

  • Tefferi A . (2007). The history of myeloproliferative disorders: before and after Damshek. Leukemia 22: 1–11.

    Article  Google Scholar 

  • Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA et al. (2007). Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110: 1092–1097.

    Article  CAS  Google Scholar 

  • Tefferi A, Vardiman JW . (2007). Classification and diagnosis of myeloproliferative neoplasms. The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22: 14–22.

    Article  Google Scholar 

  • Tefferi A . (2008). Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol 83: 491–497.

    Article  CAS  Google Scholar 

  • Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E et al. (2007). Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110: 375–379.

    Article  CAS  Google Scholar 

  • Wang XD, Reeves K, Luo F, Xu LA, Lee F, Clark E et al. (2007). Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol 8: R255.

    Article  Google Scholar 

  • Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE et al. (2008). Efficacy of TG101348 a selective JAK2 inhibitor in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13: 311–320.

    Article  CAS  Google Scholar 

  • Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG . (2006). Expression of JAK2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107: 4274–4281.

    Article  CAS  Google Scholar 

  • Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A . (2006). Essential thrombocythemia beyond the first decade: life expectancy long-term complication rates prognostic factors. Mayo Clin Proc 81: 159–166.

    Article  Google Scholar 

  • Xiao S, Nalabolu SR, Aster JC, Ma J, Abruzzo L, Jaffe ES et al. (1998). FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet 18: 84–87.

    Article  CAS  Google Scholar 

  • Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S et al. (2006). Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE 1: e18.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. SmartAnalyst, New York, NY, USA

    C Kumar

  2. Oncology Drug Discovery, Research and Development, Bristol-Myers Squibb, Princeton, NJ, USA

    A V Purandare, F Y Lee & M V Lorenzi

Authors
  1. C Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A V Purandare
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Y Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M V Lorenzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M V Lorenzi.

Additional information

Conflict of interest

Drs Lorenzi, Purandare and Lee are employees and shareholders of Bristol-Myers Squibb. Dr Kumar is an employee of SmartAnalyst.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kumar, C., Purandare, A., Lee, F. et al. Kinase drug discovery approaches in chronic myeloproliferative disorders. Oncogene 28, 2305–2313 (2009). https://doi.org/10.1038/onc.2009.107

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2009.107

Keywords

This article is cited by

Search

Advanced search

Quick links